A Bayesian Dose Finding Design for Clinical Trials Combining a Cytotoxic Agent With a Molecularly Targeted Agent

Journal of the Royal Statistical Society. Series C: Applied Statistics - United Kingdom
doi 10.1111/rssc.12072
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2013English

A Bayesian Dose-Finding Design for Drug Combination Clinical Trials Based on the Logistic Model

Pharmaceutical Statistics
StatisticsProbabilityPharmacology
2014English

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2015English

Solithromycin: A New Ketolide Antibacterial Agent in Clinical Trials

International Journal of Clinical & Medical Microbiology
2018English

Two Stage Adaptive Optimal Design With Applications to Dose-Finding Clinical Trials

English

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

British Journal of Cancer
Cancer ResearchOncology
2009English

Operating Characteristics of Restrictions on Skipping Dose Level for Adaptive Dose-Finding Method in Two-Agent Phase I Trials

Japanese Journal of Biometrics
2015English

A Bayesian Dose-Finding Design Incorporating Toxicity Data From Multiple Treatment Cycles

Statistics in Medicine
EpidemiologyStatisticsProbability
2016English

Delayed Adverse Events in Phase I Trials of Molecularly Targeted and Cytotoxic Agents

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy